Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Lymphocytic Lymphoma (SLL): early-phase trial registry
8 of 15 indexed Small Lymphocytic Lymphoma (SLL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Small Lymphocytic Lymphoma (SLL): 15 US clinical trials tracked, 8 recruiting.
Small Lymphocytic Lymphoma (SLL) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Nurix Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition small-lymphocytic-lymphoma-sll
OPEN 8 | RECR 53% | LATE 0 | EARLY 13 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
Small Lymphocytic Lymphoma (SLL) lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Lymphocytic Lymphoma (SLL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Lymphocytic Lymphoma (SLL) is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Small Lymphocytic Lymphoma (SLL) research.
Nurix Therapeutics accounts for 3 of 15 trials (20%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Small Lymphocytic Lymphoma (SLL) trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Small Lymphocytic Lymphoma (SLL) research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06788639
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics
NCT07221500
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07030400
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Dana-Farber Cancer Institute
NCT05168930
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Massachusetts General Hospital
NCT06849713
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Heart, Lung, and Blood Institute (NHLBI)
NCT07428707
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT03625037
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Memorial Sloan Kettering Cancer Center
NCT04419519
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
NCT03788291
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Genzyme, a Sanofi Company
NCT00694590
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Lymphocytic Lymphoma (SLL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Lymphocytic Lymphoma (SLL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Lymphocytic Lymphoma (SLL) page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Small Lymphocytic Lymphoma (SLL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nurix Therapeutics sponsors the most Small Lymphocytic Lymphoma (SLL) trials on record, review their full trial history before evaluating a specific study. See Nurix Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Lymphocytic Lymphoma (SLL) condition card totals 15 registered trials; most-linked intervention NX-5948; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.